Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 in symptomatic knee osteoarthritis
2020-006104-17Phase 2Active
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in knee osteoarthritis (OA) comparing DFV890 with Placebo (2 arms). Primary endpoint: KOOS pain change at week 12. Started Jun 2021; status: active.
02
Drugs
DFV890
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2020-006104-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006104-17.